Risk attribution — Ressie Abernathy

v1.0 · cal 2026-05-22

Component breakdown showing every feature that contributed to this patient's risk score.

Computed = stored(J vs J)Open patient detail

Computed score

100

Group J · Stage IV / progressing

Stored A–J score

Group J · Stage IV / progressing

Score buildup

Baseline 5 + +181 positive = 100

BaselineDemographicSymptomComorbidityImagingProcedurePathologyTreatmentResponse

Demographic

Subtotal +5

Age ≥ 70
Advanced age is an independent risk factor for PDAC.
Evidence: Current age 95· Threshold: 70 years
+5

Symptom

Subtotal +39

Abdominal pain at age ≥ 50
Unexplained abdominal pain in a patient over 50 warrants pancreas evaluation.
Evidence: Onset 2025-03-07· Triggers PANDA group C
+14
Jaundice
Painless jaundice is a hallmark presentation of pancreatic head adenocarcinoma.
Evidence: Onset 2025-03-27
+13
Weight loss at age ≥ 50
Unintentional weight loss after 50 raises concern for occult malignancy.
Evidence: Onset 2025-03-17
+12

Comorbidity

Subtotal +13

Has chronic condition(s)
Chronic disease burden warrants ongoing surveillance.
Evidence: 5 active conditions
+13

Imaging

Subtotal +10

CT of abdomen on record
Imaging suggests the patient has been worked up for pancreatic concern.
Evidence: CT on 2025-09-23
+10

Procedure

Subtotal +42

EUS performed
EUS is the highest-resolution modality for sub-cm pancreatic lesions; performance implies clinical concern.
Evidence: Endoscopic ultrasonography of pancreas on 2025-07-08· Triggers PANDA group G
+20
Tissue diagnosis procedure
Biopsy or resection indicates definitive workup or treatment.
Evidence: EUS-guided fine needle aspiration of pancreas on 2025-07-11
+22

Pathology

Subtotal +40

Pancreatic tumor confirmed
Confirmed pancreatic malignancy is the defining factor for groups H–J.
Evidence: Malignant neoplasm of tail of pancreas· Triggers PANDA group H
+25
Stage IV disease
Metastatic disease puts the patient in the highest-risk group with palliative-intent management.
Evidence: Pancreatic adenocarcinoma TNM stage IV
+15

Treatment

Subtotal +20

Active chemotherapy
Active cytotoxic therapy implies confirmed malignancy with treatment intent.
Evidence: Gemcitabine 1000 MG/M2 Injection, Nab-paclitaxel 125 MG/M2 Injection· Triggers PANDA group I
+20

Response

Subtotal +12

Patient deceased
Score retained for cohort/historical analytics; treatment intent is post-mortem.
Evidence: Death recorded 2010-03-09
+12

The Risk Engine computed group (J) is derived purely from the feature contributions above. The stored A–J group (J) comes from the cascade classifier in scripts/classify-risk.ts. Divergence between the two indicates a classifier rule that the scoring weights haven't captured, or vice versa — useful for calibration.